Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?
Objective: The COVID-19 vaccine is known to instigate an inflammatory response that impacts cancer testing. We aimed to evaluate carbohydrate antigen 125 (CA-125) trends in gynecologic oncology patients in surveillance following COVID-19 vaccination to inform clinical practice. Methods: This was a s...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578923000097 |
| _version_ | 1811166413225721856 |
|---|---|
| author | Elizabeth Thayer Lindsay Walsh Katherine Leung Sharmilee Korets |
| author_facet | Elizabeth Thayer Lindsay Walsh Katherine Leung Sharmilee Korets |
| author_sort | Elizabeth Thayer |
| collection | DOAJ |
| description | Objective: The COVID-19 vaccine is known to instigate an inflammatory response that impacts cancer testing. We aimed to evaluate carbohydrate antigen 125 (CA-125) trends in gynecologic oncology patients in surveillance following COVID-19 vaccination to inform clinical practice. Methods: This was a single institution retrospective study of patients who received a COVID-19 vaccine while undergoing surveillance of gynecologic cancers with serial serum CA-125 measurements. CA-125 levels from the three months before and after vaccination were included in analysis. Differences between mean and median pre- and post-vaccination CA-125 levels for each patient were calculated. The mean and median of these differences were calculated, as well as the distribution of change. Demographic and cancer-related variables were also recorded. Results: Twenty-six patients who received a COVID-19 vaccine and were followed with surveillance serum CA-125 levels were identified. The mean age was 68.2 years; 92 % received a two-vaccine series. Forty-six percent had endometrial cancer and 54 % had ovarian cancer. The mean change from pre- to post-vaccine mean CA-125 level was 0.16 (±7.17) U/mL and the median change from pre- to post-vaccine median CA-125 level was −0.30 (IQR 3.66) U/mL. The range in change from pre- to post-vaccine mean was −16.50 to 24.00 U/mL, with 73 % of patients between −4 and +4 U/mL. Conclusion: We found no clinically significant change in CA-125 level after patients under surveillance for gynecologic cancers were vaccinated against COVID-19, suggesting that that the vaccine does not impact the utility of CA-125 as a tool to monitor disease in this population. |
| first_indexed | 2024-04-10T15:51:55Z |
| format | Article |
| id | doaj.art-9196e58b12d446d3b069db800d8daaf5 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-04-10T15:51:55Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-9196e58b12d446d3b069db800d8daaf52023-02-11T04:15:50ZengElsevierGynecologic Oncology Reports2352-57892023-02-0145101140Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?Elizabeth Thayer0Lindsay Walsh1Katherine Leung2Sharmilee Korets3Departments of Obstetrics and Gynecology, University of Massachusetts Chan Medical School and UMass Memorial Healthcare, 119 Belmont St, Worcester, MA 01605, USAUniversity of Massachusetts Chan Medical School, 55 Lake Ave North, Worcester, MA 01655, USADepartments of Obstetrics and Gynecology, University of Massachusetts Chan Medical School and UMass Memorial Healthcare, 119 Belmont St, Worcester, MA 01605, USADivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, UMass Memorial Healthcare, 119 Belmont St, Worcester, MA 01605, USAObjective: The COVID-19 vaccine is known to instigate an inflammatory response that impacts cancer testing. We aimed to evaluate carbohydrate antigen 125 (CA-125) trends in gynecologic oncology patients in surveillance following COVID-19 vaccination to inform clinical practice. Methods: This was a single institution retrospective study of patients who received a COVID-19 vaccine while undergoing surveillance of gynecologic cancers with serial serum CA-125 measurements. CA-125 levels from the three months before and after vaccination were included in analysis. Differences between mean and median pre- and post-vaccination CA-125 levels for each patient were calculated. The mean and median of these differences were calculated, as well as the distribution of change. Demographic and cancer-related variables were also recorded. Results: Twenty-six patients who received a COVID-19 vaccine and were followed with surveillance serum CA-125 levels were identified. The mean age was 68.2 years; 92 % received a two-vaccine series. Forty-six percent had endometrial cancer and 54 % had ovarian cancer. The mean change from pre- to post-vaccine mean CA-125 level was 0.16 (±7.17) U/mL and the median change from pre- to post-vaccine median CA-125 level was −0.30 (IQR 3.66) U/mL. The range in change from pre- to post-vaccine mean was −16.50 to 24.00 U/mL, with 73 % of patients between −4 and +4 U/mL. Conclusion: We found no clinically significant change in CA-125 level after patients under surveillance for gynecologic cancers were vaccinated against COVID-19, suggesting that that the vaccine does not impact the utility of CA-125 as a tool to monitor disease in this population.http://www.sciencedirect.com/science/article/pii/S2352578923000097CA-125COVID-19 vaccinationGynecologic cancer surveillance |
| spellingShingle | Elizabeth Thayer Lindsay Walsh Katherine Leung Sharmilee Korets Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable? Gynecologic Oncology Reports CA-125 COVID-19 vaccination Gynecologic cancer surveillance |
| title | Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable? |
| title_full | Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable? |
| title_fullStr | Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable? |
| title_full_unstemmed | Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable? |
| title_short | Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable? |
| title_sort | surveillance of gynecologic cancer patients post covid 19 vaccine are ca 125 levels reliable |
| topic | CA-125 COVID-19 vaccination Gynecologic cancer surveillance |
| url | http://www.sciencedirect.com/science/article/pii/S2352578923000097 |
| work_keys_str_mv | AT elizabeththayer surveillanceofgynecologiccancerpatientspostcovid19vaccineareca125levelsreliable AT lindsaywalsh surveillanceofgynecologiccancerpatientspostcovid19vaccineareca125levelsreliable AT katherineleung surveillanceofgynecologiccancerpatientspostcovid19vaccineareca125levelsreliable AT sharmileekorets surveillanceofgynecologiccancerpatientspostcovid19vaccineareca125levelsreliable |